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Introduction
Pancreatic cancer is a highly aggressive malignancy, with <50% patients surviving beyond 6 months after the diagnosis (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . Because chemotherapeutic options only marginally prolong life, the current mortality of patients with pancreatic cancer is nearly identical to its incidence. Therefore, there is an urgent need to elucidate the pathogenesis of pancreatic cancer and explore new possibilities for diagnosing and treating it.
MicroRNAs (miRNAs) constitute a class of small non-coding RNA molecules (21) (22) (23) (24) (25) nucleotides) that function as post-transcriptional gene regulators. They can function as oncogenes or tumour suppressors (8, (17) (18) (19) (20) (21) . Therefore, they have been increasingly recognised as useful biomarkers for various human cancers. In pancreatic cancer, the overexpression of several miRNAs including microRNA-21 (miR-21), microRNA-31 (miR-31), microRNA-155 (miR-155), , micro-RNA-210 (miR-210) and microRNA-222 (miR-222) is higher than that in normal pancreatic tissues and are unfavourable prognostic factors (2, 3, 10, (12) (13) (14) 22, 23) .
The term 'the CpG island methylator phenotype' (CIMP) has been repeatedly used over the past decade to describe CpG island promoter methylation in various human malignancies (1, (24) (25) (26) (27) (28) . CIMP represents a distinct form of epigenetic instability in colorectal cancer (20, 24, 27, 29) , causing most sporadic colorectal cancers with microsatellite instability (MSI) through the epigenetic inactivation of MLH1. We recently reported that a CIMP-positive status and MLH1 methylation were detected in 12% and 3.9% of pancreatic cancers (1) . Our results also showed that CIMP positivity is associated with an unfavourable prognosis of pancreatic cancer (1) . CIMP may be useful not only for molecular characterization but also for the assessment of a response to treatment in various human cancers (25) ; however, miRNAs specific to CIMP status in pancreatic cancers remain largely unknown.
Against this background, we chose to examine which molecular changes could represent new biomarkers of malignancy in pancreatic cancers. In this study, we conducted miRNA array analysis to detect miRNA molecules potentially associated with malignancy and to examine whether they could be used as diagnostic biomarkers and therapeutic targets using a specimen database of 248 pancreatic ductal adenocarcinomas (PDACs).
Materials and methods

Histopathological evaluations of pancreatic cancer tissue specimens
In total, 248 tissue specimens of UICC stage II PDAC from patients who had undergone surgical treatment at Sapporo Medical University Hospital and Teine Keijinkai Hospital between 1998 and 2013 were collected and analysed. It is challenging to explore new possibilities for treating pancreatic cancer at UICC stages III or IV because the survival rate in these cases is very low. Therefore, in this study, we focused on stage I and II cases only. In our database, the number of UICC stage I cases was very small (N = 11) compared with the number of stage II cases (N = 248). For this reason, we included stage II cases only. Histological findings related to pancreatic cancer specimens were evaluated by pathologists who were blinded to the clinical and molecular information. Overall survival (OS) was defined as the time from the surgical treatment of pancreatic cancer to death by any cause or the last follow-up. The patients were followed until death or until July 2015, whichever came first. Informed consent was obtained from all patients before specimen collection. This study was approved by the institutional review boards of the three participating institutions and complied with the tenets of the Helsinki Declaration.
RNA extraction and microRNA (miRNA) array analysis
Total RNA was extracted from formalin-fixed paraffin-embedded (FFPE) tissues using the miRNeasy FFPE Kit (Qiagen, Valencia, CA). The TaqMan® Array Human MicroRNA A+B Cards Set v3.0 (Applied Biosystems, Foster City, CA) was used for simultaneous measurement of the expression of 760 miRNAs on a microfluidic PCR platform. In brief, 1 μg of total RNA was reverse transcribed using the Megaplex Pools Kit (Applied Biosystems), following which miRNAs were amplified and detected by PCR with specific primers and TaqMan probes. PCR was run in the 7900HT Fast RealTime PCR system (Applied Biosystems) and SDS 2.2.2 software (Applied Biosystems) was used for comparative analysis of the cycle threshold (ΔC T ). U6 snRNA (RNU6B; Applied Biosystems) served as an endogenous control. ΔC T was calculated by subtracting the C T values of U6 from the C T values of the gene of interest. Expression of each miRNA in the tumour samples was calculated using the equation 2 −ΔCT , where ΔC T = (C T miRNA − C T U6).
Quantitative reverse transcription-PCR (qRT-PCR) of miR-21, miR-31 and microRNA-196b
miR-21-5p, miR-31-5p and microRNA-196b (miR-196b)-5p expression levels were analysed by quantitative RT-PCR using the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems) and TaqMan MicroRNA Assays (Applied Biosystems), as previously described (1) . In brief, 5 ng of total RNA were reverse transcribed using specific stem-loop RT primers, following which they were amplified and detected by qRT-PCR with specific primers and TaqMan probes. PCR was run in triplicate using the 7500 Fast Real-Time PCR System (Applied Biosystems). SDS v1.4 software (Applied Biosystems) was used for comparative ΔC T analysis. We defined high expression level groups of miR-21, and miR-31 as the fourth level (Q4) in a quartile as previously described (1) and miR-196b as the second level in a dichotomous category.
DNA extraction and pyrosequencing of KRAS analysis
Genomic DNA was extracted from FFPE tissues using the QIAamp DNA FFPE Tissue Kit (Qiagen) (17) . Using the extracted genomic DNA, PCR and targeted pyrosequencing were performed for KRAS (codon 12/13/61/146) as previously described (1).
Sodium bisulfite treatment and Real-Time PCR (MethyLight) to measure promoter methylation of CACNA1G, CDKN2A (p16), IGF2, MLH1 and RUNX3 Bisulfite modification of genomic DNA was performed using the BisulFlashTM DNA Modification Kit (Epigentek, Brooklyn, NY) (1). We quantified DNA methylation in four CIMP-specific promoters [CACNA1G, CDKN2A (p16), IGF2 and RUNX3] and MLH1 using Real-Time PCR (MethyLight) (1) . CIMP positive status was defined as the presence of three/four or more methylated promoters [CACNA1G, CDKN2A (p16), IGF2 and RUNX3] and CIMP negative was defined as the presence of zero/four to two/four methylated promoters as previously described (1).
Pancreatic cancer cell line and miRNA transient transfection
The human pancreatic cancer cell line PK-45P (RCB0241) provided by the RIKEN BRC (Supplementary Figure 1 , available at Carcinogenesis Online) was utilised. Total RNA was extracted from cell pellets using TRIzol Reagent (Invitrogen by Life Technologies, Carlsbad, CA). Here, 5 nmol/l of miR-196b mimic, 50 nmol/l of miR-196b inhibitor and a negative control (Ambion, Austin, TX) were transfected into the pancreatic cancer cell line. Cells were transfected using Lipofectamine 2000 (Invitrogen by Life Technologies), in accordance with the manufacturer's instructions.
Assays for proliferation and invasion
The proliferation of miRNA transfectants was analysed by measuring the uptake of tritiated thymidine in the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (MTT assay; Sigma Aldrich, St. Louis, MO). In brief, transfected cells were seeded into 96-well plates to Cell invasion was performed using the CytoSelect 24-well Cell Invasion Assay kit (Cell Biolabs, Inc., San Diego, CA), following the manufacturer's directions. This kit included polycarbonate membrane with 8-μm pores that had been precoated with basement membrane matrix.
The PK-45P cell suspension containing 1.0 × 10 6 cells/ml of serum-free medium with 5 nmol/l of the miR-196b mimic or the negative control was added to the inside of each insert. Each insert was then transferred to a lower well that was filled with 500 μl of RPMI containing 10% fetal bovine serum as a chemoattractant. After incubation for 48 h, the inserts were removed; the non-invading cells were then removed using cotton-tipped swabs, and the invading cells were fixed, stained and analysed under a microscope (Olympus, Tokyo, Japan). Cells were counted in four random fields per membrane.
Statistical analysis
The JMP (version 10) software applications were used for all calculations (SAS Institute, Cary, NC). To assess associations among the clinical, pathological and molecular characteristics, we used either the χ 2 test or Fisher's exact test. To compare mean patient ages, analysis of variance was performed.
The Kaplan-Meier method and log-rank test were performed to assess the association between miR-196b expression status of pancreatic cancer and patient mortality. To adjust the results for confounders, we used multivariate Cox proportional hazards regression models to calculate a hazard ratio (HR) according to tumour miR-196b expression status of pancreatic cancer.
The multivariate model initially included tumour location in the pancreas (head, body or tail), KRAS mutation status (in codon 12/13/61/146; present versus absent), CIMP status (CIMP positive versus CIMP negative) and miR-21 and miR-31 expression levels (high versus low expression levels). To avoid overfitting, variables in the final model were selected using backward stepwise elimination with a threshold of P = 0.10.
Results
Detection of high-level miR-196b expression in pancreatic cancer tissue in miRNA array analysis
Using laser capture microdissection method, we have collected and extracted RNA of the pancreatic cancer tissues from FFPE tissues of pancreatic cancer patients. In contrast, all samples of normal pancreatic ductal epithelium were selectively isolated from the FFPE tissues of normal pancreatic regions using the MMI Cellcut plus microdissection system (MMI, Eching, Germany).
To examine the miRNA expression signature in pancreatic cancer, 14 pancreatic cancer tissues were randomly selected from the pancreatic cancer specimens for miRNA array analysis. Median expression levels in the pancreatic cancer group were compared with those in the normal pancreatic duct group (N = 5). MiRNA array data revealed differential expression in only miR-196b (P < 0.05 by Mann-Whitney U test) between the two groups ( Table 1) . Of the 760 miRNAs, miR-196b was up-regulated the most often (9.78-fold change, P = 0.0014).
To examine the miRNA expression signature in CIMP-positive pancreatic cancer, miRNA array analysis was performed. The results showed that CIMP was positive in four specimens and negative in 10; however, the miRNA array data revealed no significant difference in expression levels in individual miRNAs between CIMP-positive and -negative specimens (data not shown).
miR-196b expressions in the pancreatic cancer cells and the corresponding cancer stroma
Using laser capture microdissection method, we have collected and extracted RNA of the pancreatic cancer cells and the corresponding cancer stroma from 10 FFPE tissues of pancreatic cancer patients, respectively and analysed miR-196b expression levels in each samples. As a result, in all of the cases, miR-196b expression levels in pancreatic cancer cells were significantly higher than those of cancer stroma (P = 0.027). In contrast, no significant difference (P = 0.08) was observed between cancer cell and the corresponding pancreatic cancer tissue (Supplementary Figure 2) .
Distribution of miR-196b expression in pancreatic cancer and association of miR-196b with clinicopathological and molecular features
We utilised 248 stage II pancreatic cancer specimens for which miR-196b expression data were available. miR-196b expression was quantified in pancreatic cancer specimens and was calculated using the equation 2 −ΔCT , where ΔC T = (C T miR-196b − C T U6). The distributions of miR-196b expression in the 248 pancreatic cancer specimens were as follows: mean, 0.0014; median, 0.00040; standard deviation (SD), 0.0033; range, 0.0-0.035 (Figure 1 ). Specimens with miR-196b expression were then dichotomised for further analysis into a low expression group (< median) and a high expression group (≥ median). Table 2 shows the clinicopathological and molecular features of pancreatic cancers according to miR-196b expression. High miR-196b expression was significantly associated with miR-21 (P = 0.0025) and miR-31 (P = 0.0001) expression.
High miR-196b expression and patient survival
The influence of high miR-196b expression on clinical outcome was assessed in stage II pancreatic cancer patients. During the follow-up of the 248 patients eligible for survival analysis, mortality occurred in 100. The median follow-up period for OS was 31.1 months. In the Kaplan-Meier analysis, significantly shorter survival was observed in the miR-196b high expression group [median OS (months): 21.2 versus 40.2; log-rank P = 0.0053; Figure 2 ].
In the univariate Cox regression analysis, compared with the miR-196b low expression group, significantly higher mortality For the multivariate analysis, we initially included tumour location, KRAS mutation status, CIMP status and miR-21 and miR-31 expression levels in the model. Similarly, compared with the miR-196b low expression group, an independent association with poorer prognosis was observed in the miR-196b highexpression group in the multivariate analysis of OS (HR: 1.66; 95% CI: 1.09-2.54; P = 0.019; Table 3 ).
Functional analysis of miR-196b expression in pancreatic cancer cell line
The mimic and inhibitor of miR-196b were transfected into PK-45P. In the proliferation assay, significantly decreased cell proliferation was observed as a result of transfection of the miR196b inhibitor ( Figure 3A) . The basement membrane invasion assay revealed enhanced invasiveness of the miR-196b mimic ( Figure 3B ) after transfection into PK-45P.
Discussion
The results of the miRNA array analysis revealed that miR-196b was the most up-regulated gene in pancreatic cancer tissue compared with normal pancreatic duct tissue. In a database of 248 patients with stage II pancreatic cancer, high miR-196b expression was associated with miR-21 and miR-31 expression. We also identified that high miR-196b expression was an unfavourable prognostic factor in pancreatic cancer patients, independent of clinicopathological and molecular features. Functional analysis demonstrated that an inhibitor of this microRNA and a mimic of it, which resulted in decreased cell proliferation and increased cancer cell invasion, respectively. These results suggest that miR-196b is an independent prognostic biomarker and therapeutic target in pancreatic cancer. The gene for miR-196b is located in a highly evolutionarily conserved region between the HOXA9 and HOXA10 genes on chromosome 7 (7p15.2) in humans (30) . Recently, several investigations have reported that target molecules of miR-196b are HOX clusters (such as A5, A9, B6, B7 and C8), FAS, PI3K/AKT/mTOR signaling pathway, Bcr-Abl expression and c-myc (18, (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) . Previous studies have reported that miR-196b is diagnostic and prognostic factor in the digestive tract cancers. In esophageal cancer tissues, miR-196b was abnormally expressed compared with that in normal tissues (41). Lu et al. (42) reported that plasma miR-196b level was substantially up-regulated in patients with oral premalignant lesions as well as in oral cancer patients and that miR-196b may be circulating biomarker for the early detection of oral cancer. In colorectal cancer, a recent study has reported that miR-196b is associated not only with BRAF mutations but also with poor prognosis after adjustment for MSI status (43) . In gastric cancer, miR-196b is one of the microRNAs found to be significantly associated with OS (44, 45) . Furthermore, in lung adenocarcinoma, acute myeloid leukemia and glioblastoma, the upregulation of miR-196b is associated with a poor prognosis (46) (47) (48) .
Previous studies have suggested that several microRNAs are associated with a poor prognosis of pancreatic cancer patients; specifically, the increased expression of miR-21, miR-31, miR-155, miR-198, microRNA-203 (miR-203), microRNA-205 (miR-205), miR-210 and miR-222 was significantly associated with a shorter disease-free survival and OS (4, (12) (13) (14) 22, 49) . Low micro-RNA-34a (miR-34a), microRNA-141 (miR-141) and microRNA-375 (miR-375) expression in pancreatic cancer tissue was also significantly correlated with shorter OS (12, 15, 22) . In the current study, using a large database, we revealed that high miR-196b expression was independently associated with a shorter prognosis in a multivariate stage-stratified Cox model. Although miR-196b has been reported to be up-regulated in pancreatic cancer tissues and to be useful as a diagnostic factor of pancreatic cancer (5, 8, 9) , this is the first study to identify an association of high miR-196b expression with an unfavourable prognosis in pancreatic cancer patients.
Our data showed that miR-196b expression levels in pancreatic cancer cells were significantly higher than those in the cancer stroma, suggesting that miR-196b is up-regulated in pancreatic cancer cells but not in the cancer stroma. The high miR196b expression level in pancreatic cancer tissues may reflect the expression levels in cancer cells. Taken altogether, miR-196b using pancreatic cancer tissue may be a useful biomarker as an alternative to laser capture microdissection for examining miR-196b expression in pancreatic cancer samples. We also found that a high miR-196b expression level was significantly associated with miR-21 and miR-31 expression in pancreatic cancers. No previous study has reported the relationship of miR196b with miR-21 and miR-31 in pancreatic cancer; therefore, the exact mechanism is still unknown. One possibility is that these oncogenic miRNAs in pancreatic cancer work synergistically because they influence networks that control innate and adaptive immunities and apoptosis by regulating signalling pathways.
With regard to the functional analysis of miR-196b, a recent study reported that the up-regulation of miR-196b promotes the proliferation and invasiveness of gastric cancer cells by regulating the PI3K/AKT/mTOR pathway (32) . Moreover, miR-196b has been reported to promote invasive and migratory phenotypes in oral cancer by targeting NME4, leading to the regulation of downstream molecules, including activating p-JNK, suppressing TIMP1 and augmenting MMP1/9 (50). The current study has revealed that in pancreatic cancer cells, the miR-196b inhibitor decreased cell proliferation. Furthermore, the miR-196b mimic promoted cell invasion, suggesting that miR-196b functions as an oncogenic miRNA in human pancreatic cancer as well as in gastric cancer and oral cancer.
CIMP is associated with both favourable and unfavourable prognoses, as well as different clinical characteristics, depending on the tumour type. In pancreatic cancer, we recently reported that a CIMP-positive status is related to poor prognosis (1) . With regard to the association of CIMP status with miRNA expression, our current miRNA array data using pancreatic cancer samples showed no significant difference in expression in individual miRNAs between CIMP-positive and CIMP-negative specimens. Further analysis using largescale samples is expected to clarify the association of miRNA expression with epigenetic alterations, including CIMP status, in pancreatic cancers.
Our current study was limited by the cross-sectional design and the potential for bias (i.e., selection bias) that could have confounded the results. Nevertheless, our multivariate regression analysis was adjusted for potential clinical and molecular confounders. Although further study is needed to confirm our results, this is an interesting first step toward the improved understanding and diagnosis of this high grade malignant disease. The importance of large-scale studies for cancer research cannot be emphasised enough. Small studies with null results are likely to remain unpublished compared with small studies with significant results; this leads to publication bias. Compared with previous studies, the present study examined the miR-196b expression status in a much larger unbiased cohort of pancreatic cancer patients.
In conclusion, a significant association of high miR-196b expression with poor prognosis was observed in pancreatic cancer patients. Our data also revealed that miR-196b played an oncogenic role and that the transfection of miR196b inhibitor had an anti-tumour effect in a pancreatic cancer cell line. These results suggest that miR-196b is a promising diagnostic biomarker and therapeutic target in pancreatic cancer.
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Supplementary data are available at Carcinogenesis online. 
